Navigation Links
Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial
Date:12/2/2009

ly in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009 and the quarterly report on Form 10-Q for the quarter ended July 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.


Contacts:
GendeLLindheim BioCom Partners
Investors                          Media
---------                          -----
info@peregrineinc.com              Barbara Lindheim
(800) 987-8256                     (212) 918-4650

SOURCE Peregrine Pharmaceuticals, Inc.


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... May 29, 2015 GeneWEAVE, ... organisms (MDROs), announced that initial feasibility data supporting ... detection and susceptibility testing from positive blood cultures ... May 31, 2015 in New Orleans, LA. The ... molecular diagnostics that can quickly detect bacteria and ...
(Date:5/29/2015)... 2015 The Academy of Model Aeronautics ... school graduates from across the nation. , The Academy ... qualified AMA Youth Members with scholarships to pursue technical ... Program has awarded nearly $900,000 to college-bound aero-modelers. The ... organizations and individuals, AMA member donations, a portion of ...
(Date:5/29/2015)... Asthma treatment could   see significant ... enter arena, says   GBI Research ... of the leading asthma brands, such as Advair (fluticasone ... global market for asthma treatment is set to witness ... New analysis from business intelligence provider GBI ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Market ... (Chem-Report ) signed a partnership agreement for quality ... authorised to distribute and sell research reports worked ... at Partners Department, commented upon the agreement: “Chem-Report ... on key petroleum and chemical markets on global ...
Breaking Biology Technology:Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 3Academy of Model Aeronautics Awards $46,500 in Scholarships to College-Bound Model Aviation Pilots 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 3Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3
... of... -- CAMBRIDGE, Massachusetts, August 26, 2010 ... ... ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
... New York State Department of Health has licensed Genelex Corporation,s ... state. The issued Clinical Laboratory Permit is for DNA testing ... 50 percent of the most commonly prescribed medicines. Research shows ... the genetic coding for these enzymes, greatly increasing their risk ...
... CFO -- LONDON, August 26, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Biology Technology:Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 2Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 3Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 4Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 5Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 6Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 7Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 8Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 9New York State Licenses Personalized Prescribing DNA Tests 2Hikma - Half Year Results Interviews With CEO and CFO 2Hikma - Half Year Results Interviews With CEO and CFO 3Hikma - Half Year Results Interviews With CEO and CFO 4Hikma - Half Year Results Interviews With CEO and CFO 5
(Date:5/29/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ) has ... Market by Solution, by Software, by Hardware, by ... report to their offering. The last ... more efficient and cost effective. This has helped ... the commercial sector. The development of 3D facial ...
(Date:5/28/2015)... , May 28, 2015 Industry analyst ... a new report titled "Markets for Self-Healing Materials: ... inorganic capsule and vascular systems, biomaterials, relevant shape ... to around $2.7 billion by 2020. ... extensive coverage of smart materials. Other recent n-tech reports ...
(Date:5/27/2015)... 2015   Codonics (codonics.com), a ... image documentation solutions and Omnicell  (omnicell.com), ... solutions, is pleased to announce their state ... Label System® (SLS), an award-winning FDA class ... Omnicell Anesthesia Workstation, helps prevent medication errors, ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... Ill. (June 18, 2012) Seeking to solve some ... source facilities at national research laboratories in the United ... Canadian Light Source and the Advanced Photon Source (APS) ... Laboratory agreed in January 2012 to a Partner User ...
... , PHILADELPHIA Healthy humans harbor an enormous and ... within their intestines. These microbial partners provide beneficial aid ... the development of a healthy immune system. In a ... , David Artis, PhD, associate professor of Microbiology, and ...
... to the simple sponge to find clues about the evolution ... a mechanism that coordinates the expression of genes that lead ... of the animal world may not be so distant after ... network," are published in the Proceedings of the National ...
Cached Biology News:Advanced Photon Source and Canadian Light Source strengthen ties 2Brothers in arms: Commensal bacteria help fight viruses 2Clues to nervous system evolution found in nerve-less sponge 2